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Burkholderia mallei the etiologic agent of glanders, causes severe disease in humans
and animals and is a potential agent of biological warfare and terrorism. Diagnosis and
treatment of glanders can be challenging, and in the absence of chemotherapeutic
intervention, acute human disease is invariably fatal. At present, there are no human
or veterinary vaccines available for immunization against disease. One of the goals of
our research, therefore, is to identify and characterize protective antigens expressed by
B. mallei and use them to develop efficacious glanders vaccine candidates. Previous
studies have demonstrated that the O-polysaccharide (OPS) expressed by B. mallei
is both a virulence factor and a protective antigen. Recently, we demonstrated
that Burkholderia thailandensis, a closely related but non-pathogenic species, can be
genetically manipulated to express OPS antigens that are recognized by B. mallei OPS-
specific monoclonal antibodies (mAbs). As a result, these antigens have become important
components of the various OPS-based subunit vaccines that we are currently developing
in our laboratory. In this study, we describe a method for isolating B. mallei-like OPS
antigens from B. thailandensis oacA mutants. Utilizing these purified OPS antigens, we
also describe a simple procedure for coupling the polysaccharides to protein carriers such
as cationized bovine serum albumin, diphtheria toxin mutant CRM197 and cholera toxin
B subunit. Additionally, we demonstrate that high titer IgG responses against purified
B. mallei LPS can be generated by immunizing mice with the resulting constructs.
Collectively, these approaches provide a rational starting point for the development of
novel OPS-based glycoconjugates for immunization against glanders.
Keywords: Burkholderia mallei , Burkholderia thailandensis, O-polysaccharide, glycoconjugate, vaccine,
immunization
INTRODUCTION
Burkholderia mallei is a non-motile, facultative intracellular,
Gram-negative bacillus that causes a debilitating disease known
as glanders. This zoonotic pathogen is an obligate animal par-
asite that is primarily responsible for disease in solipeds (i.e.,
horses, mules, and donkeys) (Howe and Miller, 1947; Redfearn
et al., 1966; Yabuuchi et al., 1992; Srinivasan et al., 2001).
Occasionally, in endemic regions, the organism may also cause
disease in humans and other mammals (Miller et al., 1948). In
equines, glanders presents as chronic or acute illnesses charac-
terized by lung involvement, ulcerative nasal/tracheal lesions and
visceral abscess formation. The clinical progression of human
glanders is similar to that observed in solipeds and may man-
ifest as chronic or acute localized infections, acute pulmonary
infections or fulminating septicemias (Howe and Miller, 1947;
Redfearn et al., 1966; Bartlett, 1998). Due to the potential use of
B. mallei as an agent of biological warfare and terrorism, there is
interest in developing effective glanders vaccines. To date, how-
ever, attempts to identify suitable candidates have been met with
limited success.
Lipopolysaccharides, commonly referred to as endotoxins, are
a major component of Gram-negative cell envelopes (Burns et al.,
2006). The “barrier function” provided by bacterial outer mem-
branes is largely due to the presence of these molecules (Nikaido,
2003). Bacterial strains expressing a “smooth” phenotype syn-
thesize LPS antigens that are composed of three covalently linked
domains: a lipid A moiety, a core region and an O-polysaccharide
(OPS) (Raetz and Whitfield, 2002). Previous studies have shown
that the OPS moieties expressed by Burkholderia pseudomallei
(etiologic agent of melioidosis) and Burkholderia thailandensis
(non-pathogenic saprophyte) are unbranched heteropolymers
consisting of disaccharide repeats having the structure -3)-β-
D-glucopyranose-(1-3)-6-deoxy-α-L-talopyranose-(1- in which
∼33% of the 6-deoxy-α-L-talopyranose (L-6dTalp) residues
possess 2-O-methyl and 4-O-acetyl substitutions while the
remainder of the L-6dTalp residues bear only 2-O-acetyl mod-
ifications (Perry et al., 1995; Brett et al., 1998, 2003; Burtnick
et al., 2002). Additionally, studies in our laboratory have also
shown that B. mallei expresses OPS antigens that are structurally
similar to those expressed by B. pseudomallei and B. thailandensis
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strains except that the L-6dTalp residues lack acetyl modifications
at the O-4 position (Burtnick et al., 2002). This phenomenon
certainly explains the ability of researchers to generate mono-
clonal antibodies (mAbs) specific for B. pseudomallei or B. mallei
OPS antigens (Anuntagool and Sirisinha, 2002; Neubauer et al.,
2005). Curiously, B. mallei isolates only appear to be capable
of expressing a restricted repertoire of structurally diverse OPS
antigens. It has even been suggested that virulent isolates of
B. mallei can be defined by one serotype (Neubauer et al., 2005).
At present, the significance of these observations with regards
to virulence and evasion of host immune responses remain to
be defined. Nonetheless, this phenomenon certainly bodes well
from a vaccine development standpoint.
Virulent isolates of B. mallei, whether of human or veterinary
origin, all appear to express smooth LPS phenotypes (Burtnick
et al., 2002; Neubauer et al., 2005). Studies conducted in 1925 by
Stanton and Fletcher demonstrated that B. malleiNCTC 120, now
recognized as a rough isolate, was avirulent in both equine and
rabbit models of infection (Stanton and Fletcher, 1925). More
recently, we have shown that B. mallei strains, including NCTC
120, expressing rough LPS phenotypes are exquisitely sensitive to
the bactericidal effects of normal human serum in comparison
to those expressing a smooth phenotype thus implicating OPS as
an important virulence determinant expressed by this pathogen
(Burtnick et al., 2002). Additionally, and germane to the present
study, Trevino et al. have shown that murine mAbs specific for
B. mallei OPS are capable of passively immunizing mice against a
lethal aerosol challenge (Trevino et al., 2006). Such findings con-
firm the protective capacity of this surface exposed antigen and
support the rationale for developing OPS-based glycoconjugates
for immunization against glanders.
In the present study, we describe the use of a variety of
approaches to facilitate the development and preliminary testing
of novel OPS-based glanders vaccine candidates. It is anticipated
that via the application of these approaches, we will gain valuable
insights toward the rational design of OPS-based glycoconjugates
for immunization against disease caused by B. mallei.
MATERIALS ANDMETHODS
STRAINS AND GROWTH CONDITIONS
The bacterial strains used in this study are described in Table 1.
Unless otherwise stated B. pseudomallei, B. thailandensis and
E. coli were grown at 37◦C on Luria Bertani-Lennox (LBL) agar
or in LBL broth. For B. mallei and its derivatives, LBL media
was supplemented with 4% glycerol (LB4G). When appropriate,
antibiotics were added at the following concentrations: 25μg/ml
zeocin (Zeo) or 15μg/ml polymyxin B (Pm) for E. coli and
5μg/ml Zeo for B. mallei. Bacterial stocks were maintained at
−80◦C as 20% glycerol suspensions. All studies with B. pseudoma-
llei and B. mallei were conducted in a CDC select agent certified
biosafety level 3 containment facility.
RECOMBINANT DNA TECHNIQUES
The plasmids and oligonucleotide primers used in this study
are described in Table 1. DNA manipulations were performed
using standardmethods. Restriction enzymes and T4 DNA Ligase
(New England BioLabs) were used according to manufacturer’s
instructions. PCR was performed using an Expand High Fidelity
PCR System (Roche Applied Science) or GoTaq DNA Polymerase
(Promega); 1M Betaine (Sigma) was included in all PCR reac-
tions. PCR was performed using the following conditions: 97◦C
for 5min; 30 cycles, each consisting of 97◦C for 45 s, 55◦C for
45 s, and 72◦C for 3min; a final extension step of 72◦C for 10min
was included. PCR and restriction digested products were puri-
fied using a QIAquick Gel Extraction Kit (Qiagen). Plasmids were
purified using a QIAprep Spin Miniprep Kit (Qiagen). Genomic
Table 1 | Strains, plasmids, and primers.
Strains Relevant characteristics Source or reference
E. coli
TOP10 General cloning strain: Pms, Zeos Invitrogen
S17-1 Mobilizing strain: Pms, Zeos Simon et al., 1983
B. pseudomallei
SZ210 DD503 derivative; wcbB Reckseidler-Zenteno et al., 2005
B. mallei
ATCC 23344 Type strain; isolated in 1944 from a human case of glanders Yabuuchi et al., 1992
GRS 23344 ATCC 23344 derivative; sucrose-resistant, sacB: Pmr, Zeos Schell et al., 2008
BM210 GRS 23344 derivative; wcbB: Pmr, Zeos This study
B. thailandensis
DW503 ATCC 700338 (E264) derivative; (amrR-oprA): Pmr, Zeos Burtnick et al., 2001
ZT0715 DW503::pZT0715: Pmr, Zeor Brett et al., 2011
Plasmids
pEX18Zeo Gene replacement vector; oriT sacB: Zeor Burtnick et al., 2010
pEXwcbB pEX18Zeo harboring wcbB with an internal 792-bp deletion: Zeor This study
Primersa
wcbB-FB 5’-GATCGGATCCGCGCGCCACTGGCCCCCGACGTAG-3’ This study
wcbB-RXb 5’-GATCTCTAGAACGATCTCTCGTGCGGGCGAGCC-3’ This study
aRestriction sites are italicized.
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DNA was purified using a Wizard Genomic DNA Purification
kit (Promega). Chemically competent E. coli TOP10 cells were
transformed as per the manufacturer’s instructions (Invitrogen).
Oligonucleotide primers were obtained from Integrated DNA
Technologies (Coralville, IA).
MUTANT CONSTRUCTION
Gene replacement experiments with B. mallei were con-
ducted using the sacB-based vector pEX18Zeo. To construct
pEXwcbB, the wcbB-FB/wcbB-RXb primer pair was used to
PCR amplify the wcbB gene (792-bp markerless, in-frame dele-
tion of the wcbB gene) from B. pseudomallei SZ210 genomic
DNA (Reckseidler-Zenteno et al., 2005). The PCR product
was then digested with BamHI and XbaI and cloned into
pEX18Zeo digested with the same enzymes resulting in plasmid
pEXwcbB.
To construct the B. mallei CPS mutant strain BM210, E. coli
S17-1 was used to mobilize pEXwcbB into B. mallei GRS
23344 via conjugative mating essentially as previously described
(Deshazer et al., 1997; Burtnick et al., 2011). Briefly, overnight
cultures of S17-1 (pEXwcbB) and GRS 23344 were pelleted by
centrifugation, resuspended together in 100 μl of 10mMMgSO4,
spotted onto LB4G agar plates and incubated for 18 h at 37◦C.
To select for transconjugants, mating mixtures were plated onto
LB-Zeo-Pm agar and incubated at 37◦C for 48 h. To select for
sucrose resistant colonies, individual transconjugants were inoc-
ulated into Yeast Tryptone (YT) broth, incubated at 37◦C for
4–5 h, and then plated onto YT medium agar containing 5%
sucrose (Hamad et al., 2009). Following incubation at 37◦C for
48 h, sucrose resistant colonies were screened for loss of the Zeo
resistance marker by replica plating onto LB4G and LB4G-Zeo.
The resolved co-integrates were screened for the presence of the
mutant allele (wcbB) by PCR.
LPS AND OPS PURIFICATION
LBL or LB4G broth (4 × 600ml in 2 L baffled Erlenmeyer
flasks) inoculated with the various B. thailandensis or B. mallei
strains described in this study were incubated overnight at 37◦C
with vigorous shaking. Cell pellets were obtained by centrifuga-
tion (10min at 8000× g) and extracted using a modified hot
aqueous-phenol procedure (Perry et al., 1995). After extraction,
the resulting phenol and aqueous phases were combined and dia-
lyzed against distilled water to remove the phenol. The dialysates
were then clarified by centrifugation (20min at 10,000× g) and
the supernatants concentrated by lyophilization. The crude LPS
preparations were solubilized at 20mg/ml in RD buffer (10mM
Tris-HCl [pH 7.5], 1mM MgCl2, 1mM CaCl2, 50μg/ml RNase
A and 50μg/ml DNase I) and incubated for 3 h with gentle shak-
ing at 37◦C. Proteinase K was then added to a final concentration
of 50μg/ml and the samples were incubated for an additional 3 h
at 60◦C, whereupon the enzymatic digests were clarified by cen-
trifugation (20min at 10,000× g). LPS was then isolated from the
supernatants as precipitated gels following successive rounds of
ultracentrifugation (3 × 2 h at 100,000× g with the pellets being
resuspended in ultrapure water between spins). After the final
spin, the gel-like pellets were resuspended in ultrapure water and
lyophilized.
To obtain purified OPS to synthesize the glycoconjugates, the
B. thailandensis ZT0715 samples were solubilized at 5mg/ml in
2% acetic acid (AcOH) and incubated for 2 h at 100◦C. The
hydrolyzed samples were cooled to room temperature, clarified
via centrifugation (20min at 10,000× g), and the supernatants
were carefully removed and lyophilized. The lyophilized sam-
ples were then solubilized at 20mg/ml in 100mM phosphate
buffered saline (pH 7.4; PBS) and clarified using 0.45μm syringe
filters. The samples were loaded onto Sephadex G-50 columns
(40 × 2.6 cm) equilibrated with PBS and eluted with the same
buffer. Fractions (6ml) were collected and assayed for carbohy-
drate using the phenol-sulfuric acid method (Dubois et al., 1956).
Carbohydrate positive fractions eluting near the column void vol-
umes (∼70ml) were pooled, extensively dialyzed against distilled
water and lyophilized. Protein and nucleic acid contamination
of the resulting OPS preparations were estimated by BCA assay
(Pierce) and A260/280measurements, respectively.
GLYCOSYL COMPOSITION ANALYSIS
Column purified OPS (200 μg) was mixed with 300 μl 1 M
methanolic HCl and incubated at 80◦C in a sealed glass tube.
After 16 h, the mixture was dried down under a stream of
dry nitrogen and co-evaporated three times with dry MeOH to
remove residual acid. After re-N-acetylation with acetic anhy-
dride (100 μl) in methanol/pyridine (2:1, 300μl), the sample was
treated with 200 μl Tri-Sil® (Pierce), incubated in a sealed tube
for 20min at 80◦C, and dried down. The residue was taken up in
2ml hexane, filtered, and dried down. The resulting TMS-methyl
glycosides were dissolved in 150 μl hexane and analyzed on an
Agilent 7890A gas chromatograph interfaced to a 5975C mass
selective detector in electron impact ionization mode. Separation
was performed on a 0.25μm EC-1 bonded phase fused silica
capillary column (30m × 0.25mm).
NMR SPECTROSCOPY
Column purified OPS samples were deuterium exchanged by dis-
solving inD2O, followed by lyophilization.The samples were then
dissolved in D2O containing a trace amount of acetone, and 1H
and 13C NMR spectra were obtained using a Varian Inova-500
MHz spectrometer at 50◦C using standard pulse sequences. 1H
and 13C chemical shifts were measured relative to the internal ace-
tone reference (δH = 2.218 ppm; δC = 33.0 ppm) (Wishart et al.,
1995).
GLYCOCONJUGATE SYNTHESIS
Glycoconjugates were synthesized using established methodolo-
gies (Jennings and Lugowski, 1981; Brett and Woods, 1996;
Conlan et al., 2002). Briefly, purified OPS samples were solubi-
lized at 5mg/ml in PBS and added to a small amber vials. To
each ml of the solutions was added 6mg (∼30mM) of sodium
meta-periodate (NaIO4; Pierce). Once the crystals had dissolved
by gentle agitation, the reaction mixtures were gently stirred at
room temperature for 40min. To remove any excess oxidizing
agent, the reaction mixtures were applied to a Zeba Desalt Spin
Columns (Pierce) equilibrated with PBS and the eluates collected.
To facilitate conjugation of the OPS antigens to cationized bovine
serum albumin (cBSA; Pierce), diphtheria toxin mutant CRM197
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(CRM197; List Biological Laboratories, Inc.) or cholera toxin B
subunit (CtxB; Sigma), the activated OPS samples were added to
small amber vials. To each ml of the OPS solutions was added
0.5, 1, 2, or 4ml of the carrier proteins (5mg/ml in PBS). After
mixing by gentle agitation, 10 μl aliquots of a sodium cyanoboro-
hydride stock (1 M NaBH3CN in 10mM NaOH) were added to
each ml of the conjugation mixtures and the reactions were gently
stirred at room temperature for 4 d. Following this, 10 μl aliquots
of a sodium borohydride stock (1 M NaBH4 in 10mM NaOH)
were added to each ml of the conjugation mixtures and the reac-
tions were stirred for 40min. The conjugate reactions were then
brought to 5ml with ultrapure water, dialyzed against distilled
water and then lyophilized. The resulting preparations were resus-
pended in ultrapure water as 1mg/ml stocks and stored at -20◦C
until required for use. BCA assays were used to quantitate the
protein concentrations of the glycoconjugate stocks.
ANTIBODY PRODUCTION
6–8 weeks old female BALB/c mice were immunized subcu-
taneously on days 0, 21, and 35 with 10 μg of the OPS1B1
glycoconjugate (∼5 μg of OPS as a conjugate) formulated with
saline, saline plus Alhydrogel 2% (500 μg/mouse; Brenntag) or
saline plus Alhydrogel 2% plus ODN 2006 (CpG; 20 μg/mouse;
InvivoGen). Unconjugated OPS and cBSA antigens (similarly for-
mulated) served as controls. Terminal bleeds were conducted
7 days after the third immunization. All procedures involving
the mice were performed according to protocols approved by the
University of South Alabama Institutional Animal Care and Use
Committee.
SDS-PAGE ANDWESTERN IMMUNOBLOTTING
The LPS and glycoconjugate samples were solubilized in 1X
SDS-PAGE sample buffer and heated to 100◦C for 5min prior
to use. Proteins were separated by electrophoresis on Novex
12% Tris-Glycine gels (Life Technologies) and visualized via
staining with Coomassie Blue R-250. For immunoblot analyses,
the LPS and glycoconjugate samples were separated on the same
12% gels and electrophoretically transferred to nitrocellulose
membranes. The membranes were blocked with 3% skim milk
in high salt Tris-buffered saline (HS-TBS; 20mM Tris, 500mM
NaCl, pH 7.5) for 60min at room temperature and then incu-
bated overnight at 4◦C using 1/1000 dilutions of the B. mallei
OPS-specific mAbs 3D11 (Research Diagnostics, Inc.) and 9C1-2
(Trevino et al., 2006) or 1/800 dilutions of the B. pseudomallei/B.
thailandensis OPS-specific mAb Pp-PS-W (Bryan et al., 1994).
To facilitate detection, the membranes were incubated for 1 h at
room temperature using 1/5000 dilutions of anti-mouse IgG (for
3D11) or IgM (for Pp-PS-W) horse radish peroxidase conjugates
(SouthernBiotech). The blots were then visualized using HRP
Color Development Reagent (Bio-Rad) or Pierce ECL Western
Blotting Substrate (Pierce).
QUANTITATION OF IMMUNOGLOBULIN TITERS BY ELISA
Ninety-six well Maxisorp plates (Nunc) were coated overnight at
4◦C with purified B. mallei BM210 LPS (10μg/ml) solubilized
in carbonate buffer (pH 9.6). The plates were blocked at room
temperature for 30min with StartingBlock T20 (TBS) Blocking
Buffer (Pierce) and then incubated for 2 h at 37◦Cwith the mouse
serum samples serially diluted in Tris-buffered saline + 0.05%
Tween 20 (TBS-T; pH 7.5) + 10% StartingBlock T20. To facil-
itate detection, the plates were incubated for 1 h at 37◦C with
1/2000 dilutions of anti-mouse IgG, IgG1, or IgG2a horse radish
peroxidase conjugates (SouthernBiotech). The plates were then
developed with TMB substrate (KPL) and read at 620 nm. The
reciprocals of the highest dilutions exhibiting ODs of >0.150
were used to determine the endpoint titers for the individual
mice. The data was plotted and analyzed using GraphPad Prism 5
(GraphPad Software Inc.). Statistical differences between geomet-
ric mean IgG titers ware assessed by Mann–Whitney rank sum
analysis with the significance set at P < 0.05.
CELL CULTURE AND OPSONOPHAGOCYTOSIS ASSAYS
The murine macrophage cell line RAW 264.7 (ATCC TIB-71)
was maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% (v/v) heat inactivated (HI) fetal bovine serum
(DMEM-10; Invitrogen) and a standard mixture of antibiotics
(100 U ml−1 penicillin, 100 μg ml−1 streptomycin and 250 μg
ml−1 amphotericin B; Sigma) at 37◦C under an atmosphere of
5% CO2. Opsonophagocytosis assays were based upon previously
described methods (Simon et al., 2011; Tennant et al., 2011).
Briefly, RAW 264.7 cells resuspended in DMEM-10 were trans-
ferred into 24-well tissue culture plates at a density of ∼1 × 106
cells/well and incubated overnight. B. malleiATCC 23344 cultures
grown to early-log phase were pelleted, resuspended at a den-
sity of ∼106 cfu/ml in DMEM containing 0.5% vehicle/adjuvant
only control or OPS1B1 mouse immune serum (pooled and
HI for 30min at 56◦C) and then incubated at 37◦C for 1 h.
RAW 264.7 monolayers were washed twice with Hanks’ Balanced
Salts Solution (HBSS; Invitrogen) prior to the addition of the
opsonized bacterial suspensions. The monolayers were incubated
with the bacteria at 37◦C under an atmosphere of 5% CO2 for 1 h
and then washed twice with HBSS to remove extracellular bacte-
ria. Infected RAW 264.7 cells were incubated in fresh DMEM-10
containing 250 μg/ml kanamycin to suppress the growth of resid-
ual extracellular bacteria. At 3 h post-infection, monolayers were
washed twice with HBSS, lysed with 0.2% (v/v) Triton X-100
(Sigma) and serial dilutions of the lysates were plated onto LB4G
agar and incubated at 37◦C for 48 h. Plate counts were used to
enumerate bacterial loads. The data was plotted and analyzed
using GraphPad Prism 5. Statistical differences were assessed by
t-test with the significance set at P < 0.05.
RESULTS AND DISCUSSION
GLYCOCONJUGATE VACCINES
Immunologically, antigens can be classified as either T cell-
dependent (TD) or T cell-independent Type 1 or Type 2 (TI-1 or
TI-2) (Mosier et al., 1977a,b). In general, proteins and peptides
are TD antigens while carbohydrates are TI-1 and TI-2 antigens
(Weintraub, 2003). Polysaccharides such as capsular antigens and
OPS are considered TI-2 antigens (Jones, 2005). Without the
involvement of T cells, TI-2 antigens do not induce immunologi-
cal memory, avidity maturation or isotype switching (Weintraub,
2003). Additionally, repeat vaccination does not evoke high anti-
body titer responses and without immunization at frequent
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intervals, antibody levels will decline (Jones, 2005). Typically,
only high molecular weight TI-2 antigens are immunogenic due
to their ability to crosslink multiple surface immunoglobulin
(sIg) molecules present on individual B cells (Mond et al., 1995;
Snapper and Mond, 1996). For this reason OPS and low molec-
ular weight capsular polysaccharides alone are often not effective
vaccine candidates.
The mechanism by which glycoconjugates stimulate immune
responses involves initial recognition by sIg molecules displayed
by antigen specific B cells. Following recognition of the carbohy-
drate component, glycoconjugates are internalized and the carrier
protein is degraded by proteolytic enzymes. Peptides are then
transported to and displayed by major histocompatibility com-
plex (MHC) class II molecules. The peptide-loaded MHC class II
molecules are then recognized by T helper (Th) cells, which pro-
vide appropriate signals through direct B cell/Th cell interactions
and via cytokine signaling processes to induce maturation of the
B cells into antibody secreting plasma and memory cells. Since
cross-linking of multiple sIg molecules is not required during
this process, glycoconjugate vaccines can be produced from low
FIGURE 1 | Western immunoblot analysis of B. thailandensis LPS
antigens. Purified B. thailandensis DW503 (WT) and ZT0715 (oacA mutant)
LPS antigens were probed with (A) the B. thailandensis OPS-specific mAb,
Pp-PS-W or (B) the B. mallei OPS-specific mAb, 3D11. The positions of
protein molecular size standards are indicated on the left.
molecular weight carbohydrates such as OPS antigens (Kuberan
and Linhardt, 2000; Lesinski and Westerink, 2001; Lockhart,
2003; Weintraub, 2003; Jones, 2005).
PURIFICATION AND CHARACTERIZATIONOF B. mallei-LIKE OPS
ANTIGENS
OPS-based glycoconjugates represent a rational approach for
immunizing against disease caused by B. mallei. To date, how-
ever, isolating OPS antigens for this purpose has been hampered
by the fact that B. mallei is a select agent requiring specialized
handling and containment practices. To address these issues, we
have begun to investigate the use of a closely related but non-
pathogenic Burkholderia species as a source of B. mallei-like OPS
antigens. By doing so, we believe that it is possible to safely and
cost-effectively produce these vaccine candidates for testing with-
out the requirement for BSL-3 containment. Previous studies
have shown that the OPS expressed by B. mallei are similar to
those produced by B. thailandensis except that they lack the 4-O-
acetyl modifications on their 6-deoxy-α-L-talopyranosyl residues
(Burtnick et al., 2002). Recently, we described the identification
and characterization of an open reading frame, designated oacA,
expressed by B. thailandensis that accounts for this phenomenon.
Utilizing the B. thailandensis and B. mallei OPS-specific mAbs,
Pp-PS-W and 3D11 respectively, Western immunoblot analy-
ses demonstrated that the OPS antigens expressed by the oacA
mutant, B. thailandensis ZT0715, were antigenically similar to
those produced by B. mallei ATCC 23344 (Brett et al., 2011).
To facilitate the construction of the glycoconjugates described
in this study, LPS-antigens were isolated from B. thailandensis
using a modified enzyme hot aqueous-phenol procedure (Brett
et al., 2003, 2011). Consistent with previous observations, only
the antigens purified from ZT0715 (oacA mutant) and not the
parent strain (DW503) were shown to react strongly by Western
immunoblotting with the B. mallei OPS-specific mAbs, 3D11
and 9C1-2 (Figure 1 and data not shown). We routinely obtain
20–25mg of OPS per liter of ZT0715 culture by column purifi-
cation of acid hydrolyzed LPS, with the resulting antigen prepa-
rations being devoid of detectable protein or nucleic acid con-
tamination as determined by BCA assay or UV spectroscopy.
To assess the structural integrity and homogeneity of the OPS
preparations, samples are also subjected to glycosyl composition
and NMR spectroscopy analyses. Using these approaches, we are
able to demonstrate that the preparations consist primarily of
the -3)-β-D-glucopyranose-(1-3)-6-deoxy-α-L-talopyranose-(1-
FIGURE 2 | Generalized scheme for the conjugation of chemically activated B. thailandensis OPS to carrier proteins.
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heteropolymer in which the L-6dTalp residues bear only 2-O-
acetyl modifications confirming their similarity to B. mallei OPS
preparations (data not shown).
CONJUGATION OF OPS TO CARRIER PROTEINS
To facilitate the coupling of B. thailandensis OPS to protein car-
riers, we have found that NaIO4 is well suited for chemically
activating the polysaccharide. The decision to use NaIO4 was
based upon several considerations including (1) the absence of
amines or carboxylates in the antigen that would favor conjuga-
tion via other methods, (2) the relative safety of the compound
FIGURE 3 | Physical analysis of B. thailandensis OPS-cBSA
glycoconjugates. (A) SDS-PAGE and Coomassie Blue staining was used to
confirm the covalent linkage of ZT0715 OPS to cBSA. The OPS + cBSA
lane represents unconjugated controls. The black arrow indicates the
position of the predominant cBSA band. The positions of protein molecular
size standards are indicated on the left. (B) Western immunoblotting was
also used to assess the antigenicity of the chemically activated/coupled
ZT0715 OPS. OPS was detected using the 3D11mAb. Lanes were loaded
with similar amounts of protein or carbohydrate to facilitate direct
comparisons. The black arrowhead indicates the position of the OPS which
binds poorly to the membrane when unconjugated.
over alternatives such as cyanogen bromide, (3) the use of reac-
tion conditions to minimize the risk of reducing alkali-sensitive
O-acetyl modifications, (4) the desire to construct neoglyco-
conjugates rather than cross-linked network conjugates (Jones,
2005). Using the approach outlined in Figure 2, reactive aldehy-
des incorporated into the core residues at the reducing termini
of B. thailandensis OPS facilitate the conjugation of the anti-
gen to carrier proteins via reductive amination. To reduce the
Schiff bases formed during the coupling reactions, NaBH3CN
was chosen as the primary reducing reagent because, unlike
NaBH4,it rapidly modifies Schiff bases but not aldehydes. Once
the OPSmoieties are coupled to carrier proteins, however, NaBH4
is then added to quench any residual aldehydes in the reaction
mixtures.
Initially, the OPS-based glycoconjugates synthesized in this
study were constructed using cBSA as the protein carrier. The
decision to use cBSA for this purpose was based on several con-
siderations including the fact that it is (i) a well characterized
immunogen, (ii) commercially available, and (iii) affordable. To
facilitate our studies, glycoconjugates were synthesized by react-
ing various ratios of chemically activated OPS and cBSA with
one another (e.g., 2:1, 1:1, 1:2, and 1:4 ratios of OPS:cBSA).
Upon conjugation of the antigens, the samples were exam-
ined by SDS-PAGE. Results of these analyses indicated that
in all instances, the OPS had covalently linked to the pro-
tein carrier as demonstrated by the shift in molecular weight
of the cBSA relative to the unconjugated control (Figure 3A).
In addition, Western immunoblotting confirmed that the struc-
tural integrity/antigenicity of the OPS moieties remained intact
after chemical activation and linkage to the protein carrier
based upon their reactivity with the mAbs, 3D11 and 9C1-2
(Figure 3B and data not shown). Furthermore, studies demon-
strated that by varying initial carbohydrate to protein ratios,
we could influence the molecular weights of the resulting gly-
coconjugates. It should be noted, however, that the glycocon-
jugates began to precipitate out of solution at the OPS:cBSA
ratio of 2:1.
FIGURE 4 | Characterization of serum immunoglobulin responses
following immunization of mice with the OPS1B1 glycoconjugate. ELISA
was used to determine the serum IgG responses of mice immunized with
OPS1B1 (filled circles) or the unconjugated controls (OPS + cBSA; open
circles). The OPS1B1 and control samples were formulated with (A) saline,
(B) saline plus Alhydrogel or (C) saline plus Alhydrogel/CpG prior to
immunization. Individual symbols represent single mouse while the black
horizontal bars indicate geometric means. ∗P < 0.05.
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Table 2 | Effect of adjuvants on serum immunoglobulin responses.
Immunogen(s) Adjuvant Antibody titersa–Terminal bleed (1 SD confidence interval)
IgG IgG1 IgG2a Ratio IgG2a:IgG1
OPS + cBSA None 12,800 (1.07e3–1.53e5) NDb ND −
OPS1B1 None 162,550 (7.67e4–3.45e5) 144,815 (6.75e4–3.11e5) 4032 (5.52e2–2.94e4) 0.028
OPS + cBSA Alhydrogel 7,184 (2.05e3–2.52e4) ND ND −
OPS1B1 Alhydrogel 364,912 (1.56e5–8.54e5) 364,912 (1.56e5–8.54e5) 2263 (1.23e3–4.16e3) 0.006
OPS + cBSA Alhydrogel/CpG 3,592 (1.76e3–7.35e3) ND ND −
OPS1B1 Alhydrogel/CpG 579,262 (2.70e5–1.24e6) 516,064 (2.14e5–1.25e6) 114,940 (3.03e4–4.37e5) 0.223
aTiters are reported as geometric means (n = 6 mice per group).
bND, not determined.
FIGURE 5 | Opsonophagocytic uptake of B. mallei by RAW 264.7
murine macrophages. Bacterial uptake in the presence of HI pooled
vehicle/adjuvant only control serum (Control; n = 6) or pooled anti-OPS1B1
immune serum (OPS1B1; n = 6) was quantitated at 3 h post-infection.
Values represent the means ± SD of three independent experiments.
∗P < 0.05.
IMMUNE RESPONSES AGAINST OPS-BASED GLYCOCONJUGATES
Studies suggest that vaccine candidates promoting T helper 1
(Th1)-like cellular and humoral immune responses will likely be
required to immunize against glanders (Amemiya et al., 2002,
2006). To examine the immunogenic potential of the cBSA-based
glycoconjugates synthesized in this study, mice were immu-
nized with either the OPS1B1 construct (49.3% protein on a
w/w basis) or unconjugated controls. The primary reason for
utilizing OPS1B1 was that of the four conjugates synthesized
in this study, OPS1B1 was the one that possessed the high-
est percentage of OPS (on a w/w basis) while still remaining
soluble. Analysis of serum samples obtained from the termi-
nal bleeds demonstrated that, in all instances, mice immunized
with OPS1B1 produced significantly higher anti-B. mallei LPS
IgG titers than those immunized with the unconjugated con-
trols (Figures 4A–C). Although the mice that were immunized
with OPS1B1 in saline exhibited impressive anti-LPS IgG lev-
els, as expected those that were immunized with the conjugate
formulated with Alhydrogel or Alhydrogel/CpG produced the
highest IgG titers (Table 2). Additionally, based upon the analy-
sis of the IgG2a:IgG1 ratios, it appears that mice immunized with
OPS1B1 formulated with saline or Alhydrogel produce T helper 2
(Th2)-like biased humoral responses while those immunized with
FIGURE 6 | Physical analysis of B. thailandensis OPS-CRM197 and
OPS-CtxB glycoconjugates. (A and C) SDS-PAGE and Coomassie Blue
staining was used to confirm the covalent linkage of ZT0715 OPS to
CRM197 or CtxB. The OPS + CRM197 or CtxB lanes represent
unconjugated controls. The black arrows indicate the positions of the
CRM197 or CtxB bands. The positions of protein molecular size standards
are indicated on the left. (B and D) Western immunoblotting was also used
to assess the antigenicity of the chemically activated/coupled ZT0715 OPS.
OPS was detected using the 3D11mAb. The black arrowheads indicate the
positions of the OPS which binds poorly to the membranes when
unconjugated.
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the conjugate formulated with Alhydrogel/CpG produce mixed
Th1/Th2-like humoral responses (Figures 4A–C and Table 2). To
assess the functional activity of the OPS1B1 antiserum, sam-
ples were examined for their ability to mediate opsonophagocytic
uptake. As shown in Figure 5, pre-incubation of B. mallei with HI
pooled anti-OPS1B1 serum, but not HI pooled vehicle/adjuvant
only control serum, significantly enhanced bacterial uptake into
RAW 264.7 murine macrophages.
CONCLUSIONS
Glanders is a re-emerging infectious disease for which no licensed
vaccines currently exist. Recent reports have demonstrated that
mAbs specific for the OPS antigen expressed by B. mallei are
passively protective in animal models of infection (Jones et al.,
2002; Nelson et al., 2004; Zhang et al., 2011; Aucoin et al.,
2012). Because of this, research in our laboratory is focused on
developing OPS-based vaccines to immunize humans and ani-
mals against diseases caused by this bacterial pathogen. In the
present study, we have detailed methodologies to facilitate the iso-
lation of highly purified preparations of B. mallei-like OPS from
B. thailandensis. In addition, we have described a simple strategy
for covalently linking the carbohydrate antigen to carrier pro-
teins. Using these approaches, we have also demonstrated that
high titer IgG responses can be raised against the carbohydrate
component of the OPS-based glycoconjugates. Based upon these
observations, studies are currently underway to test the protec-
tive capacity of our prototype glycoconjugates in animal models
of glanders. Due to obvious limitations regarding the use of
cBSA as a carrier for vaccine development, efforts are ongo-
ing to explore the use of licensed carriers (e.g., CRM197, CtxB,
ExoA etc.) for this purpose (Figure 6). Additionally, studies are
being planned to investigate how differing adjuvants might be
used to promote more robust Th1-like IgG responses against
the carbohydrate component of the glycoconjugates. Collectively,
these studies should provide important insights toward the ratio-
nal design of efficacious glanders vaccine candidates. It is also
anticipated that similar methodologies will be amenable to the
development of OPS-based glycoconjugates for immunization
against melioidosis.
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